---
title: "Transgene Biotek Ltd (526139) — Share Price, Financials & Analysis"
symbol: "526139"
company: "Transgene Biotek Ltd"
canonical: "https://tapetide.com/stocks/526139"
isin: "INE773D01018"
nse_symbol: "TRANSGENEBIOTEKLTD"
bse_code: "526139"
sector: "Healthcare Services"
industry: "Healthcare Service Provider"
market_cap_cr: 21.55
generated_at: "2026-09-13T18:39:51.226Z"
---

# Transgene Biotek Ltd (526139)

Canonical page: https://tapetide.com/stocks/526139

## Company

- **NSE Symbol:** TRANSGENEBIOTEKLTD
- **BSE Code:** 526139
- **ISIN:** INE773D01018
- **Sector:** Healthcare Services
- **Industry:** Healthcare Service Provider
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** transgenebiotek.com

## About

Incorporated in 1990, Transgene Biotek Ltd 
is in the business of Research & Development[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:46:49.887205Z.

- **Market Cap:** ₹21.55 Cr
- **Classification:** Microcap
- **P/E (reported):** -13.6
- **EPS (TTM):** ₹-0.21
- **EPS (reported):** ₹0
- **Book Value:** ₹1.11
- **Price to Book:** 2.59
- **Dividend Yield:** 0%
- **ROE:** -6.74%
- **ROCE:** -0.33%
- **Debt to Equity:** 2.05
- **Revenue (yearly):** ₹0.21 Cr
- **Net Income:** ₹-1.65 Cr
- **EBITDA:** ₹-0.54 Cr
- **52-Week High:** ₹4.5
- **52-Week Low:** ₹1.83
- **RSI (14):** 50.58

## Tapetide Score

- **Score:** 37 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Flat
- **Percentile:** 8.7 (of 4473 scored stocks)
- **Confidence:** 91%
- **Data coverage:** 81%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 11.41 | 9% |
| growth | 13.65 | 9% |
| momentum | 50.8 | 12% |
| ownership | 50 | 24% |
| quality | 25.78 | 22% |
| valuation | 43.25 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
- Company has a low return on equity of -9.77% over last 3 years.
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 1.2% | 1.2% | — |
| ebitda margin growth | 0% | 360.83% | 44.3% | 78.91% |
| net income growth | 20% | 135.71% | 20% | 13% |
| revenue growth | -50% | -79% | 52% | 4% |
| roce | -44.44% | -17.5% | -92.53% | -3.93% |
| roe | -15.22% | 10.13% | -21.9% | -85.64% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.08 | 0.08 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 |
| Expenses | 0.17 | 0.16 | 0.32 | 0.46 | 0.13 | 0.17 | 0.62 | 0.18 | 0.13 | 0.1 | 0.33 | 0.12 |
| Operating Profit | -0.12 | -0.11 | -0.27 | -0.41 | -0.07 | -0.09 | -0.54 | -0.13 | -0.08 | -0.05 | -0.28 | -0.06 |
| OPM % | -240 | -220 | -540 | -820 | -116.67 | -112.5 | -675 | -260 | -160 | -100 | -560 | -100 |
| Other Income | 0.04 | 0.04 | 0.05 | 0.65 | 0.04 | 0.04 | 0.04 | 0 | 0 | 0 | 0.15 | 0 |
| Interest | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.19 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 |
| Profit before tax | -0.13 | -0.12 | -0.27 | 0.2 | -0.07 | -0.09 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 | -0.39 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -0.13 | -0.12 | -0.27 | 0.2 | -0.07 | -0.09 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 | -0.39 |
| EPS in Rs | -0.02 | -0.02 | -0.04 | 0.03 | -0.01 | -0.01 | -0.09 | -0.06 | -0.05 | -0.05 | -0.06 | -0.05 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.12 | 0.07 | 0 | 0.17 | 0.09 | 0.06 | 0.23 | 0.26 | 0.21 | 0.21 |
| Expenses | 2.22 | 0.75 | 0.87 | 0.7 | 0.55 | 0.68 | 0.83 | 1.38 | 0.75 | 0.68 |
| Operating Profit | -2.1 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.6 | -1.12 | -0.54 | -0.47 |
| OPM % | -1750 | -971.43 | — | -311.76 | -511.11 | -1033.33 | -260.87 | -430.77 | -257.14 | -223.81 |
| Other Income | 7.37 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.18 | 0.78 | 0.15 | 0.15 |
| Interest | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.24 | 1.06 | 1.1 |
| Depreciation | 9.89 | 9.89 | 9.9 | 9.91 | 9.92 | 4.95 | 0.09 | 0.09 | 0.2 | 0.19 |
| Profit before tax | -5.65 | -8.79 | -10.97 | -10.44 | -10.4 | -6.01 | -0.65 | -0.67 | -1.65 | -1.61 |
| Tax % | 13.98 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Net Profit | -6.44 | -8.79 | -10.96 | -10.43 | -10.4 | -6.01 | -0.66 | -0.68 | -1.65 | -1.61 |
| EPS in Rs | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 | -0.22 | -0.21 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | -16.9 | -23.34 | -32.13 | -43.1 | -53.53 | -58.39 | -64.4 | -65.06 | -65.74 | -67.39 |
| Borrowings | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.01 | 13.11 | 14 | 14.52 | 17.14 |
| Other Liabilities | 123.18 | 124.28 | 123.77 | 123.75 | 123.31 | 117.71 | 117.87 | 117.62 | 119.54 | 118.14 |
| Total Liabilities | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.1 | 142.35 | 142.33 | 144.09 | 143.66 |
| Fixed Assets | 61.16 | 50.97 | 41.1 | 31.2 | 21.32 | 11.4 | 6.45 | 6.36 | 7.96 | 9.63 |
| CWIP | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.09 |
| Other Assets | 134.86 | 133.71 | 133.58 | 133.68 | 133.69 | 133.73 | 133.93 | 134 | 134.16 | 133.94 |
| Total Assets | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.1 | 142.35 | 142.33 | 144.09 | 143.66 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.1 | 0 | 0 | 1.2 | -0.01 |
| Cash from Investing Activity | 0 | 3.05 | 1.74 | 0 | -0.03 | -0.1 | -0.01 | 0 | -1.7 | 0.15 |
| Cash from Financing Activity | 0 | -2.37 | 0 | -0.2 | 0 | 0 | 0 | 0 | 0.78 | -0.36 |
| Net Cash Flow | 0.02 | 0.05 | 0 | -0.06 | -0.01 | 0 | -0.01 | 0 | 0.28 | -0.22 |
| Free Cash Flow | 0.02 | 2.74 | -0.01 | 0.14 | -0.02 | 0.1 | 0 | 0 | -0.5 | 0.14 |
| CFO/OP | -1 | 30 | 256 | -16 | -2 | -22 | 0 | 0 | -107 | 2 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 13.04 | 30.42 | 52.14 | — | 21.47 | 40.56 | 60.83 | 15.87 | 14.04 | 17.38 |
| Inventory Days | — | 365 | 365 | 1460 | 121.67 | — | 156.43 | — | — | — |
| Days Payable | — | 5018.75 | 3528.33 | 13870 | 1460 | — | 1199.29 | — | — | — |
| Cash Conversion Cycle | 13.04 | -4623.33 | -3111.19 | — | -1316.86 | 40.56 | -982.02 | 15.87 | 14.04 | 17.38 |
| Working Capital Days | -14339.29 | -39967.5 | -62519.29 | — | -29092.65 | -34593.89 | -57365.83 | -15933.04 | -16509.23 | -21361.19 |
| ROCE % | -14.69 | -10.97 | -17.91 | -22.11 | -26.56 | -32.31 | -20.01 | -2.07 | -1.75 | -2.36 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 71.73% | 70.1% | 71.45% | 71.75% | 71.74% | 71.87% | 71.88% | 71.89% | 71.85% | 71.85% | 71.81% | 71.7% |
| Others | 4.63% | 6.26% | 4.92% | 4.61% | 4.62% | 4.5% | 4.48% | 4.48% | 4.51% | 4.51% | 4.55% | 4.66% |
| No. of Shareholders | 11360 | 12220 | 12426 | 12766 | 12963 | 13307 | 13583 | 13475 | 13461 | 13545 | 13767 | 13817 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 0 / 7 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2.78 | Sell |
| EMA (10) | 2.8 | Sell |
| SMA (20) | 2.82 | Sell |
| EMA (20) | 2.82 | Sell |
| SMA (50) | 2.93 | Sell |
| EMA (50) | 2.89 | Sell |
| SMA (100) | 2.99 | Sell |
| EMA (100) | 2.92 | Sell |
| SMA (200) | 2.83 | Sell |
| EMA (200) | 3.04 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 45.65 | Neutral |
| MACD (12,26,9) | -0.04 | Sell |
| Stochastic (14,3,3) | 33.73 | Neutral |
| ADX (14) | 15.88 | Neutral |
| Williams %R (14) | -66 | Neutral |
| ATR (14) | 0.23 | High Volatility |
| ROC (12) | -1.77 | Sell |
| Stoch RSI (14) | 53.97 | Neutral |
| UO (7,14,28) | 46.82 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99c57c29-eb62-43ed-9310-3377616ffe57.pdf) |
| 2026-08-07 | [Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On August 07 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=254e654d-7f7d-4586-a5d0-66683778c9ad.pdf) |
| 2026-07-23 | [Board Meeting Intimation for Intimation Of The Board Meeting.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=219c5730-fe4b-4df9-98e9-888f07dfc657.pdf) |
| 2026-07-22 | [Compliance-57 (5) : intimation after the end of quarter](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7e0ffb2-e3a0-4ceb-9e59-87a0f57c8d14.pdf) |
| 2026-07-22 | [Statement Of Deviation & Variation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e2cf9aeb-24ab-4c41-9fbd-8303a3d70613.pdf) |
| 2026-07-22 | [Compliance-57 (4) : Prior intimation to the beginning of the quarter](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c85a3764-8cef-4ed5-8811-1f9811beafdf.pdf) |
| 2026-07-13 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=869b41fa-a01c-4702-baa8-6996f49b6b07.pdf) |
| 2026-06-20 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2fc59a1-9ca4-4688-9256-867bcc18cc83.pdf) |
| 2026-06-02 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38dc1aa8-e8d7-4d60-8ca5-d4b0043769a8.pdf) |
| 2026-05-29 | [Board Meeting Outcome for Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c33946b8-f981-4dbf-a47d-d54c0251b1e9.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-07 | [1)The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026. 2) The Board Considered And Approved The Limited Review Report (Standalone & Consolidated) Of The Compa](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6e404335-6b2a-4a9d-9a24-13c995819040.pdf) |
| 2026-05-29 | [Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef8409ac-96b8-4ee0-a442-8e91976de074.pdf) |
| 2026-02-13 | [Dear Sir/Madam This Has Reference To Our Letter Dated January 28 2026. 1) The Board Has Considered And Approved The Unaudited Consolidated & Stand-Alone Financial Results Of The Company For The Quarter Ended 31.12.2025 In Accordance With The Indian](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2775582a-a506-4093-b32e-9f8282dd0a26.pdf) |
| 2025-11-14 | [Un-Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30 2025. (Copy Enclosed)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe8b88a6-dcb6-4d26-a16f-9dbf1d869eea.pdf) |
| 2025-08-07 | [The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=092e41dc-a33c-41eb-a6b2-99aa56083c35.pdf) |
| 2025-05-07 | [Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=20e7eeab-6278-4d5a-a834-f0d770a82971.pdf) |
| 2025-01-24 | [The Board Has Considered And Approved The Unaudited Consolidated & Standalone Financial Results Of The Company For The Quarter Ended 31.12.2024 In Accordance With The Indian Accounting Standards (IND-](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a088f6b5-e0b5-4f10-93be-0c516d02090d.pdf) |
| 2024-11-13 | [Revised Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42c8e7bc-001a-4246-83c1-dd98efe38490.pdf) |
| 2024-11-12 | [Outcome Of Board Meeting.This Has Reference To Our Letter Dated 03Rd November 2024.At The Meeting Of The Board Of Directors Of The Company Held On Tuesday 12Th November 2024, The Following Decisions Were Taken:1. Un- Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024. (Attached).2.Limited Review Report (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024. (Attached).](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5dda17bd-1e51-4df0-a862-711c9151559d.pdf) |
| 2024-08-10 | [1) The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2024.2) The Board Considered And Approved The Limited Review Report (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b5ea06b-6e22-4f90-8e78-05a56cfe0c80.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 3 Feb - SEBI recovery order Jan 19, 2026 seeking Rs.38 lakh; bank accounts frozen, assets prohibited. | [Declaration Under Clause 36 Of Listing Agreement With BSE PROHIBITORY ORDER NO. RRD/SRO/1166/2026/1 - SEBI 3 Feb - SEBI recovery order Jan 19, 2026 seeking Rs.38 lakh; bank accounts frozen, assets prohibited.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9862f87e-ad40-4409-8164-3f7071b22f09.pdf) |
| 28 Jan - Board meeting on 13-Feb-2026 to approve unaudited standalone and consolidated results for quarter ended 31-Dec-2025. | [Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday, 13Th February, 2026 28 Jan - Board meeting on 13-Feb-2026 to approve unaudited standalone and consolidated results for quarter ended 31-Dec-2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/53bca3a1-11d3-45e5-abe9-0d90b6d45c48.pdf) |
| 24 Mar - Trading window closed from 01.04.2026 until 48 hours after audited results for quarter/year ended 31.03.2026. | [Closure of Trading Window 24 Mar - Trading window closed from 01.04.2026 until 48 hours after audited results for quarter/year ended 31.03.2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/acd8d518-44e9-4091-860a-0f330f2605de.pdf) |
| 17 Feb - Transcript of Earning Conference call for the quarter and nine month period ended December 31, 2025, conducted after the meeting of Directors held on 11th … | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 17 Feb - Transcript of Earning Conference call for the quarter and nine month period ended December 31, 2025, conducted after the meeting of Directors held on 11th …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/315543b1-a3fb-440c-a891-61b9d95d3c69.pdf) |
| 13 Feb - Q3 FY2026 unaudited results: revenue Rs5.45L, quarter loss Rs37.38L, YTD loss Rs119.59L | [Board Meeting Outcome for Outcome Of Board Meeting 13 Feb - Q3 FY2026 unaudited results: revenue Rs5.45L, quarter loss Rs37.38L, YTD loss Rs119.59L](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8ede8d89-e990-417d-8045-7fab89ef74f0.pdf) |
| 13 Apr - Transgene Biotek confirms it does not qualify as a Large Corporate under SEBI norms. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 13 Apr - Transgene Biotek confirms it does not qualify as a Large Corporate under SEBI norms.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d2c5951e-f2c4-4f78-a13e-e5b3a8b38f72.pdf) |
| 13 Apr - Regulation 57 not applicable as no non-convertible securities exist for Q4 FY2026. | [Compliance-57 (4) : Prior intimation to the beginning of the quarter 13 Apr - Regulation 57 not applicable as no non-convertible securities exist for Q4 FY2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/78a541c6-678b-4c9d-bebd-422caff96a66.pdf) |
| 13 Apr - Regulation 32 non-applicability intimated for quarter ended 31 March 2026; no public, rights or preferential issue. | [Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI LODR) Regulations, 2015 For The Quarter Ended On 31St March 2026. 13 Apr - Regulation 32 non-applicability intimated for quarter ended 31 March 2026; no public, rights or preferential issue.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/96b886da-70a3-484b-a54a-82b37044010e.pdf) |
| 13 Apr - Reg. 57(5) not applicable for quarter ended 31 March 2026; no non-convertible securities issued. | [Compliance-57 (5) : intimation after the end of quarter 13 Apr - Reg. 57(5) not applicable for quarter ended 31 March 2026; no non-convertible securities issued.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4818ff7e-b3a9-45b6-8963-8941c4d46395.pdf) |
| 12 Jan - Reg 32(1) not applicable for quarter ended 31-Dec-2025; no public/rights/preferential issues. | [Statement Of Deviation & Variation 12 Jan - Reg 32(1) not applicable for quarter ended 31-Dec-2025; no public/rights/preferential issues.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1b6a73a8-cfcc-46e2-8682-2b4b0e2faee7.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2024 | [Concall - Sep 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/595219ca-8746-4cbc-841f-53ec9ebc9bc4.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fa7c3b0c-c4a9-4dc9-bcf6-58f8ec331cef.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8daf0e82-4a0e-49bd-8299-cf3199245e2b.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ef847a58-d5b9-4f12-9301-5972e88d674f.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/840bd3eb-0cb7-4b31-b7ce-a948eed15190.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7bd89746-4df0-451c-91f3-0d6bf80ae3db.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2667ca19-7bc6-4185-9f12-142cad7e9a15.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7c4d5c74-a657-49fd-9e7a-4fab59f64d2e.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/26e42952-2ed5-4bc5-84d6-6ca9a41ca0a4.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e69286a0-070b-4343-b621-c537ee51a62f.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/526139/75477526139.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/526139/70503526139.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/526139/65153526139.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/526139/5261390319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/526139/5261390318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/526139/5261390317.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:39:51.226Z.